Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. - Wikidata - wikimedia - TriplyDB

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

http://www.wikidata.org/entity/Q34896439

about

Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies Therapeutic implications of autoantibodies in rheumatoid arthritis The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses Use of the tumor necrosis factor-blockers for Crohn's disease Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.Relationship between anti-CCP antibodies and oxidant and anti-oxidant activity in patients with rheumatoid arthritis Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis.Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease.Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents Lessons for lupus from tumour necrosis factor blockade.Adalimumab for rheumatoid arthritis.Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis.Autoantibody production in anti-TNF-alpha-treated patients.Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems.Rheumatoid factors: clinical applications.Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.Autoantibodies to posttranslational modifications in rheumatoid arthritis.Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients.Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful?Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosis.Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis.Transcriptional profiling of leukocytes from rheumatoid arthritis patients before and after anti-tumor necrosis factor therapy: A comparison of anti-nuclear antibody positive and negative subsets.Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis.Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha.Interleukin-6 receptor inhibitor tocilizumab ameliorates periodontal inflammation in patients with rheumatoid arthritis and periodontitis as well as tumor necrosis factor inhibitors.

P2860

Q21195370-8901C5D1-EF8D-4081-9667-CC9EA5849065 Q24627677-F03C5F86-1523-4A60-8BBF-093934A187EC Q26744033-479171DD-5F3C-47E0-9C5E-1732F1107647 Q27022645-4002FC00-E8DB-45A5-B0E5-EC98399CFAE9 Q27030762-45FACBB4-565B-4749-BBB6-ADA919CD9A8C Q30647378-11E2856C-40A2-4D51-8D54-1EFF98BFA8D9 Q34575204-8BCA0FEB-9695-4348-B4CC-B509BC1EAD03 Q34586496-B34469FE-C378-4581-9645-E7A6BB7519F4 Q34613963-62B2F96A-D833-41F1-9FE8-679174F9B064 Q35207886-419AC050-4FFB-4CD1-B038-9780CE30C17D Q35475541-B138EA27-0F7D-4E73-898C-D5A3F77047C8 Q35577993-77626839-15F8-4C7B-B228-A568926AD62E Q35645491-2574C9FB-010C-4D05-A01A-68096AF7BE3E Q35760039-9C7C39E6-6345-42C1-BFAD-BE45CB921893 Q36579988-516A149C-E6DC-41DA-8D54-1425B9C6B50F Q36677012-721AAE93-5FAA-4CF8-B9B1-44C72404EAE9 Q36708319-D3D4B17B-BBC2-4B1B-862C-F7F11540B251 Q36908127-56FCD0C4-6648-494A-8514-081A9ECC1818 Q36958337-EC0F11D6-0255-46F3-85CE-A3AC21009272 Q37000109-B2CA5A2C-22B4-4DB2-9DFF-F40E49B1953A Q37270787-2138B2AF-D5DD-4543-9BFB-F093D3529E90 Q37353700-764E4FC2-EF6D-4624-9CF3-D6B5C526CEEB Q37624583-D99C20FF-A49E-4BB0-8DBC-7624BB2A306D Q37693939-DD3E8B62-BBED-4DE6-9E79-B56F7BB72589 Q38236144-34067A63-FBC8-4EBD-9E83-DA4518C49E55 Q38411852-B95BBDA4-4970-4FC3-B72D-8E6A18498DE0 Q38857820-6785EFBE-4A5C-40D6-8B53-5391B0A7C187 Q39920872-DC0278FE-139C-4ADB-9CFF-9B6A9E792DA0 Q40329877-0DB58B3F-DE9B-4136-B58F-7EC1E2018FF9 Q42247134-07790AE5-2536-40B1-B1EE-662CB92ADF49 Q46401991-BA50F086-CABE-4FA4-9992-259246A3F2B7 Q48192268-15DD7F73-8199-4760-A84A-00513884898D Q55077160-CE7D3010-4D3B-4A5A-AB06-73BA1C584D40

P2860

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.

http://www.wikidata.org/entity/Q34896439

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Adalimumab clinical efficacy i ...... a one-year prospective study.

@ast

Adalimumab clinical efficacy i ...... a one-year prospective study.

@en

Adalimumab clinical efficacy i ...... a one-year prospective study.

@nl

type

label

Adalimumab clinical efficacy i ...... a one-year prospective study.

@ast

Adalimumab clinical efficacy i ...... a one-year prospective study.

@en

Adalimumab clinical efficacy i ...... a one-year prospective study.

@nl

prefLabel

Adalimumab clinical efficacy i ...... a one-year prospective study.

@ast

Adalimumab clinical efficacy i ...... a one-year prospective study.

@en

Adalimumab clinical efficacy i ...... a one-year prospective study.

@nl

P1433

Q34896439-009EA872-857A-4CB6-9C30-8C85381AF41B

P1476

Q34896439-55FAA689-C482-4758-B20A-82862917FD24

P2093

Q34896439-20B98BB0-DCFC-4D39-AC70-03A234BE5ED8

Q34896439-300B6F8F-EE07-48D4-AA57-957B7650CBD3

Q34896439-30AB0DFC-C29F-422F-893B-CD0834217C89

Q34896439-44B3B5A5-D08E-43DF-A4B9-2A96F1A420D2

Q34896439-9422AFFF-085F-41BE-9D8F-5AAF649DE813

Q34896439-BDE75FE4-1946-44B2-AE2A-6C21FB46C88F

P2860

Q34896439-04A16648-31AF-4725-B529-54C99ED3D9DF

Q34896439-04D163C0-D9A7-4F68-A357-DA42ED25768A

Q34896439-0BF6DE19-1804-4A9F-859A-12420F8777B2

Q34896439-0E791536-DEE6-4658-A298-CD43C43C826F

Q34896439-0FBA92CF-9959-4104-981A-E635D3BFBBB7

Q34896439-14565606-B1D5-4C31-8A02-2E4A6F3AF784

Q34896439-234203BC-2662-4421-85ED-24B2D330439F

Q34896439-23445910-E1BD-4708-A5E3-8F7C6467DA99

Q34896439-3069F510-F41A-4D02-A5E4-26EB6D33507B

Q34896439-361A8916-C447-44BC-9AF7-20A789264208

P2888

Q34896439-E2FBDCDD-C657-4FBF-85E8-7823A34729B2

P304

Q34896439-F8FD2F0A-7870-4180-B9BC-84613C1515A7

P31

Q34896439-467AED77-A050-4D7C-9FE0-451A109E73BD

P356

Q34896439-DBC99147-1566-48CC-A2D3-5AB72FF95AA2

P433

Q34896439-14B81507-4BAE-4441-A8E0-D50F34A7D42E

P478

Q34896439-AA4A80CF-0817-46AE-A861-9B005B5D9FA8

P50

Q34896439-0E166953-64E0-45BD-80A2-6DCB65F9CD06

Q34896439-42463EDC-7775-4529-A475-81BFEEDBFF00

P577

Q34896439-6B9B210A-A466-4126-8363-6C1F998CA3A9

P5875

Q34896439-EABB1AB1-5A57-487A-ADCB-C6A96999D4EF

P6179

Q34896439-B76C5B93-6D5B-4EA0-A767-55F21D65086A

P698

Q34896439-E745B286-3B26-4A6B-B436-E7B762DD8735

P921

Q34896439-9250E077-11F6-4B02-BECA-5E9F637B813F

Q34896439-E1CC9CFF-994D-47FA-BF17-51554147A87A

P932

Q34896439-8EA377CA-4543-4041-B091-714252FF970A

P356

P1433

Arthritis Research and Therapy

P1476

Adalimumab clinical efficacy i ...... a one-year prospective study.

@en

P2093

Carola Cruini

http://www.w3.org/2001/XMLSchema#string

Donata Dell' Acqua

http://www.w3.org/2001/XMLSchema#string

Fabiola Atzeni

http://www.w3.org/2001/XMLSchema#string

Germana Cecchini

http://www.w3.org/2001/XMLSchema#string

Mario Carrabba

http://www.w3.org/2001/XMLSchema#string

Simona de Portu

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Anticardiolipin antibodies in rheumatoid arthritis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner.

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Infliximab treatment for rheumatic disease: clinical and radiological efficacy

P2888

P304

R3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR1851

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Piercarlo Sarzi-Puttini

Pier Luigi Meroni

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7414386

http://www.w3.org/2001/XMLSchema#string

P6179

1026547930

http://www.w3.org/2001/XMLSchema#string

P698

16356192

http://www.w3.org/2001/XMLSchema#string

P921

P932

1526573

http://www.w3.org/2001/XMLSchema#string